![Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/ed8fc363-c6de-4dbe-bc2d-1aea4a4870bf/gr1.jpg)
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
![Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-023-02321-8/MediaObjects/41591_2023_2321_Fig1_HTML.png)
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine
Mectronic Medicale - π΄π βππβ-π‘ππβ πππ£πππ, πππ πππππ π‘π πππππ π‘βπ π‘βππππππ π‘ πππ π‘βπ π‘ππππ πππ π ππππ₯ππππ πππ ππππππ‘ππ£π π‘βπππππ¦: πΆπππ π£ππ¨π¦! Designed and built entirely ...
![GBV-MIG Project-Challenges of Integrating Gender Analysis in Research- Evie Tastsoglou Nina Sahraoui - YouTube GBV-MIG Project-Challenges of Integrating Gender Analysis in Research- Evie Tastsoglou Nina Sahraoui - YouTube](https://i.ytimg.com/vi/7x8W3LBj0gE/hq720.jpg?sqp=-oaymwE7CK4FEIIDSFryq4qpAy0IARUAAAAAGAElAADIQj0AgKJD8AEB-AH-CYAC0AWKAgwIABABGFogWihlMA8=&rs=AOn4CLDhuVeu-lilxPbki7IzGKwwfA1Hqw)
GBV-MIG Project-Challenges of Integrating Gender Analysis in Research- Evie Tastsoglou Nina Sahraoui - YouTube
![Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/209b827d-c7bc-4235-8c71-c999e28e9c68/gr1.jpg)
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology
![Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy | Nature Communications Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-20688-x/MediaObjects/41467_2020_20688_Fig1_HTML.png)
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy | Nature Communications
STECF 13-07 - DCF NPs guidelines plus MS reports.pdf - Data Collection Framework - European Commission
![Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ... Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...](https://www.thelancet.com/cms/asset/a8001e13-49e3-44c0-b050-179d0a0a5858/gr1.jpg)
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...
![CRISPR/Cas-mediated plant genome editing: outstanding challenges a decade after implementation: Trends in Plant Science CRISPR/Cas-mediated plant genome editing: outstanding challenges a decade after implementation: Trends in Plant Science](https://www.cell.com/cms/attachment/29ae3bb4-941b-46ef-9d4f-8d69fba19d8f/gr1.jpg)